Hillsdale Investment Management Inc. Buys 7,500 Shares of Bausch Health Companies Inc (NYSE:BHC)

Hillsdale Investment Management Inc. increased its stake in shares of Bausch Health Companies Inc (NYSE:BHC) by 2.2% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,900 shares of the company’s stock after purchasing an additional 7,500 shares during the quarter. Hillsdale Investment Management Inc.’s holdings in Bausch Health Companies were worth $8,594,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in BHC. Parkside Investments LLC bought a new position in shares of Bausch Health Companies during the second quarter worth $557,000. Capital Wealth Planning LLC bought a new position in shares of Bausch Health Companies during the second quarter worth $368,000. Swiss National Bank boosted its position in shares of Bausch Health Companies by 5.6% during the second quarter. Swiss National Bank now owns 1,165,060 shares of the company’s stock worth $29,392,000 after purchasing an additional 62,100 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management raised its holdings in shares of Bausch Health Companies by 1.5% during the second quarter. B & T Capital Management DBA Alpha Capital Management now owns 56,292 shares of the company’s stock worth $1,420,000 after acquiring an additional 834 shares during the period. Finally, Ardevora Asset Management LLP raised its holdings in shares of Bausch Health Companies by 23.8% during the second quarter. Ardevora Asset Management LLP now owns 1,788,520 shares of the company’s stock worth $45,106,000 after acquiring an additional 343,900 shares during the period. 53.70% of the stock is currently owned by institutional investors and hedge funds.

BHC stock traded up $0.42 during midday trading on Friday, hitting $21.30. The company’s stock had a trading volume of 2,662,200 shares, compared to its average volume of 3,134,013. The company has a debt-to-equity ratio of 8.94, a current ratio of 1.21 and a quick ratio of 0.92. Bausch Health Companies Inc has a twelve month low of $17.20 and a twelve month high of $28.45. The company’s fifty day moving average price is $23.72 and its 200 day moving average price is $23.90. The stock has a market capitalization of $7.42 billion, a P/E ratio of 5.30, a PEG ratio of 0.25 and a beta of 0.76.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.03). Bausch Health Companies had a negative net margin of 10.88% and a positive return on equity of 52.12%. The business had revenue of $2.15 billion during the quarter, compared to analyst estimates of $2.15 billion. During the same quarter in the previous year, the firm posted $0.93 earnings per share. The firm’s quarterly revenue was up 1.1% on a year-over-year basis. Equities analysts expect that Bausch Health Companies Inc will post 4.24 EPS for the current fiscal year.

In other Bausch Health Companies news, EVP Christina Ackermann sold 3,418 shares of Bausch Health Companies stock in a transaction on Monday, August 12th. The shares were sold at an average price of $22.45, for a total value of $76,734.10. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 11.87% of the stock is currently owned by insiders.

BHC has been the topic of a number of research analyst reports. Piper Jaffray Companies set a $29.00 price objective on shares of Bausch Health Companies and gave the stock a “buy” rating in a report on Tuesday, June 11th. ValuEngine upgraded shares of Bausch Health Companies from a “strong sell” rating to a “sell” rating in a report on Monday, July 29th. TD Securities upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $28.00 price objective on the stock in a report on Thursday. Zacks Investment Research upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating and set a $27.00 price objective on the stock in a report on Tuesday, May 21st. Finally, Wells Fargo & Co restated a “sell” rating on shares of Bausch Health Companies in a report on Monday, July 15th. Three analysts have rated the stock with a sell rating, three have issued a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $29.68.

About Bausch Health Companies

Bausch Health Companies Inc develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through four segments: Bausch + Lomb/International, Salix, Ortho Dermatologics, and Diversified Products.

Read More: Why is the price target of stocks important?

Want to see what other hedge funds are holding BHC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bausch Health Companies Inc (NYSE:BHC).

Institutional Ownership by Quarter for Bausch Health Companies (NYSE:BHC)

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.